PerkinElmer, Inc. (NYSE:PKI) insider Andrew Okun sold 6,699 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $120.00, for a total transaction of $803,880.00. Following the transaction, the insider now directly owns 17,009 shares of the company’s stock, valued at $2,041,080. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

PKI opened at $118.81 on Friday. The company has a current ratio of 1.85, a quick ratio of 1.30 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $13.33 billion, a PE ratio of 25.73, a PEG ratio of 1.74 and a beta of 1.37. PerkinElmer, Inc. has a 1-year low of $62.91 and a 1-year high of $121.44. The firm has a 50-day moving average price of $102.34 and a two-hundred day moving average price of $92.22.

PerkinElmer (NYSE:PKI) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.70 by $0.87. PerkinElmer had a net margin of 9.87% and a return on equity of 18.41%. The firm had revenue of $811.91 million during the quarter, compared to analysts’ expectations of $703.32 million. During the same quarter last year, the company posted $1.00 EPS. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. On average, research analysts predict that PerkinElmer, Inc. will post 4.4 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 6th. Stockholders of record on Friday, October 16th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a dividend yield of 0.24%. The ex-dividend date is Thursday, October 15th. PerkinElmer’s dividend payout ratio is 6.83%.

A number of equities analysts have recently commented on PKI shares. Citigroup raised their price objective on shares of PerkinElmer from $70.00 to $85.00 and gave the stock a “neutral” rating in a report on Monday, April 20th. UBS Group lifted their price target on shares of PerkinElmer from $95.00 to $96.00 and gave the company a “neutral” rating in a report on Thursday, May 7th. Stifel Nicolaus lifted their price target on shares of PerkinElmer from $95.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday. Wells Fargo & Co lifted their price target on shares of PerkinElmer from $105.00 to $130.00 and gave the company an “equal weight” rating in a report on Wednesday. Finally, Needham & Company LLC started coverage on shares of PerkinElmer in a report on Monday, July 13th. They set a “hold” rating for the company. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. PerkinElmer has an average rating of “Hold” and a consensus price target of $95.13.

Large investors have recently modified their holdings of the company. Profund Advisors LLC acquired a new stake in shares of PerkinElmer during the 4th quarter worth approximately $211,000. DNB Asset Management AS grew its position in shares of PerkinElmer by 8.4% during the 2nd quarter. DNB Asset Management AS now owns 13,861 shares of the medical research company’s stock worth $1,360,000 after buying an additional 1,071 shares during the period. APG Asset Management N.V. grew its holdings in PerkinElmer by 59.8% during the first quarter. APG Asset Management N.V. now owns 144,148 shares of the medical research company’s stock valued at $10,851,000 after purchasing an additional 53,918 shares during the period. Boston Trust Walden Corp grew its holdings in PerkinElmer by 8.7% during the second quarter. Boston Trust Walden Corp now owns 167,465 shares of the medical research company’s stock valued at $16,427,000 after purchasing an additional 13,404 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ grew its holdings in PerkinElmer by 6.7% during the first quarter. Skandinaviska Enskilda Banken AB publ now owns 8,000 shares of the medical research company’s stock valued at $602,000 after purchasing an additional 500 shares during the period. Institutional investors own 93.34% of the company’s stock.

PerkinElmer Company Profile

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.

Read More: How is net asset value different from market price?

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.